Suggested remit: To appraise the clinical and cost effectiveness of selinexor with bortezomib and low-dose dexamethasone within its marketing authorisation for treating relapsed refractory multiple myeloma.
Status In progress
Process STA 2018
ID number 3797

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
25 August 2020 - 23 September 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
05 November 2019 In progress. DHSC referral received

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance